BridgeBio Pharma, Inc.
BBIO
$68.55
$2.603.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.02% | -35.31% | -81.63% | -71.08% | -24.10% |
| Total Depreciation and Amortization | -7.41% | -10.55% | -14.73% | -13.89% | -10.75% |
| Total Amortization of Deferred Charges | -14.30% | 1.66% | 51.90% | -- | -- |
| Total Other Non-Cash Items | 2,689.05% | 1,138.02% | 546.72% | 1,701.91% | -90.09% |
| Change in Net Operating Assets | -142.27% | -259.37% | -313.58% | -293.00% | 174.90% |
| Cash from Operations | 11.28% | 14.37% | -29.90% | -58.07% | 17.00% |
| Capital Expenditure | -389.92% | -17.58% | 15.90% | 51.83% | 88.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 100.00% | 57.14% | -- |
| Other Investing Activities | -275.11% | -137.81% | -118.74% | -67.43% | -44.63% |
| Cash from Investing | -280.13% | -140.29% | -120.91% | -67.84% | -43.50% |
| Total Debt Issued | -13.26% | -7.89% | 205.56% | 205.56% | 138.89% |
| Total Debt Repaid | 100.00% | 3.05% | 3.05% | 3.05% | 3.05% |
| Issuance of Common Stock | 424.79% | -89.43% | -92.58% | -97.16% | -98.30% |
| Repurchase of Common Stock | -80.38% | -703.37% | -532.36% | -443.61% | -490.03% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 3.66% | 34.82% | -161.95% | -96.79% | -126.74% |
| Cash from Financing | 60.39% | -52.00% | 209.41% | 45.23% | -8.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 420.00% | -138.51% | 304.04% | -10.35% | 53.93% |